Gregory Richard J. sold 3,038 shares in ImmunoGen, Inc. (NASDAQ:IMGN) for $236,056 in transaction occurred on 2019/01/07. After making this transaction, the Executive VP & CSO owns a direct stake of 16,010 shares, worth $1,265,260, as per the last closing price. On 2018/11/06 Goldberg Mark Alan, Director at IMGN, purchased 30,000 shares at an average price of $5.76 per share. The new stake is valued at $288,368.
Separately, it had been reported that some other IMGN insiders also took part of the insider trading activity. VP & Chief Medical Officer, Berkenblit Anna had divested 5,851 shares for $132,769 through a trade on 2018/10/16. Following this activity, the insider holds 46,808 shares worth $711,642 as of recent close. Wall Street’s most bullish ImmunoGen, Inc. (NASDAQ:IMGN) analysts are predicting the share price to blow past $20 per share during the next 12 months. The current median share price forecast by them is $14.5, suggesting that the stock could increase 170.52% in that time frame. The average price target of $13.38 calls for a nearly 149.63% increase in the stock price.
ImmunoGen, Inc. (IMGN) trading activity significantly improved as the volume at ready counter increased to 3,807,169 shares versus 2,632,135 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 3,075,410 shares. The share price dropped -7.43% in recent trade and currently has a stock-market value of $789.1M. The shares finished at $5.36, after trading as low as $5.27 earlier in the session. It hit an intraday high Tuesday at $5.86. The stock is now 41.05% above against its bear-market low of $3.8 on December 24, 2018. It has retreated -150.19% since it’s 52-week high of $13.41 reached in March. Now the market price is down -39.84% on the year and up 11.67% YTD.
IMGN’s 50 day simple moving average (SMA 50) price is $5.09 and its 200-day simple moving average (SMA 200) price is $8.08. The company’s stock currently has a total float of 146.64M shares. Its weekly volatility is hovering around 9.78% and felt 7.35% volatility in price over a month. On the upside, the share price will test short term resistance at around $5.72. On a downside, the stock is likely to find some support, which begins at $5.13. The failure to get near-term support could push it to $4.91.
It had seen a new analyst call from Piper Jaffray, which initiated the stock at Overweight on September 07. Analysts at RBC Capital Mkts, started covering the stock on February 08 with a Outperform rating. Analysts at H.C. Wainwright, made their first call about the stock on January 31, recommending it is Buy. RBC Capital Mkts analysts came out with bullish views on July 06 when the call was made. They think the stock is now Outperform compared to to their prior call for Sector Perform.
Also, it is trading at rather expensive levels at just over 16.75x price/book and 9.93x price/sales. IMGN’s ROE is -684.8%, which is also considerably worse than the industry’s ROE of 10.21%. It’s also very liquid in the near term, with a current ratio of 4.6. The stock has a debt/capital of 0.04.
Shares of ImmunoGen, Inc. (IMGN) have gained 12.6% since the company’s last earnings report. Over the past 12 fiscal quarters, ImmunoGen, Inc. (NASDAQ:IMGN) has topped consensus earnings estimates in 4 quarters (33%), missed earnings in 7 quarters (58%), whereas at 1 occasion EPS met analyst expectations. IMGN last reported earnings on February 08, 2019 when it released Dec-18 results that exceeded expectations. The company raked in -$0.28 per share, -97.71% change on the same period last year. That was better than consensus for -$0.32. Revenue for the recent quarter stood at $13.79 million, down -65% on last year and above the $12.27 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $8.2 million to $17.5 million, which should be compared with $15.32 million generated last year. EPS is seen in a range of -$0.41 to $0.15, against the -$0.26 reported a year ago.